Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
What We Know, What We Don't Know
back to table  

 

What we know

What we don’t know

1.

AD is defined by the presence of abundant extracellular amyloid plaques and intracellular tau tangles in neocortex, but cases have been reported with no tangles or with few plaques

If plaque and tangles are typical but not necessary and sufficient for AD, what is their role?


Comments
  Comment by:  Andre Delacourte, ARF Advisor
Submitted 7 February 2007  |  Permalink Posted 8 February 2007

I believe the statement " but AD cases have been reported with no tangles or with few plaques" is a scientific blunder and should be removed.

On the one hand, not all dementia cases are due to Alzheimer disease (AD). On the other, tangles or plaques are found in aging (which one could call "infra-AD").

Statistically, you can find non-Alzheimer dementia, with the load of lesions due to aging/infra-AD. If the nature of dementia is not known in those cases, which happens sometimes, you can say that you are dealing with AD with unusual levels of lesions. But you are simply wrong in stating that AD can occur without tangles or with few plaques, unless you demonstrate that clearly.

View all comments by Andre Delacourte


  Comment by:  Jacob Mack
Submitted 22 February 2007  |  Permalink Posted 28 February 2007

Most of the primary literature and latest textbooks reveal that amyloid beta plaques and tangles are most often associated with AD, and that most other pathologies of the brain that are absent of the aforementioned proteins can be either determined or that AD can be relatively safely ruled out. AD has become a disease of too many "subtypes." If we are going to classify many different, pathological presentations as AD, we had better deliver more compelling evidence from research to not only help ourselves, but inform the public with greater accuracy.

View all comments by Jacob Mack

  Comment by:  Jurgen Claassen (Disclosure)
Submitted 8 May 2007  |  Permalink Posted 1 June 2007

This issue can't be resolved without getting lost in semantics. The clinical diagnosis of Alzheimer disease is based on consensus (NINCDS-ADRDA). Therefore, the statement that "cases of AD have been reported with no tangles and few plaques" translates into: there have been case-reports of patients who, in live, fulfilled clinical criteria for AD, but who, on autopsy, had few plaques or no tangles." We can simply conclude that these patients are false-positive inclusions of the diagnostic test criteria.

The discussion should be split in two:
1. Consider all subjects with plaques and tangles. Then, let's argue why the clinical presentation differs that much (i.e., some are considered " normal", others have different AD severity)
2. Consider that all dementias have clinical overlap. Occasionally, patients with vascular dementia, FTD, Lewy body dementia/PDD will end up meeting the NINCDS_ADRDA criteria for AD.

View all comments by Jurgen Claassen

  Submit a Comment

 
Cast your vote and/or make a comment on this page. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Polls
 
Should the FDA be allowed to use data from overseas clinical trials?

Absolutely, we are running out of viable subjects in the U.S.
 9
 
Yes, so long as the data is reliable
 31
 
No, the trials are not as rigorous
 3
 
No, the data should be repeated in the U.S.
 5
 
No, the drug sponsors are just trying to cut corners
 3
 
Responses: 51
 
 
 
 
 
Archived Polls
 
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad